Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year High – Here’s Why

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $6.48 and last traded at $6.41, with a volume of 1795255 shares changing hands. The stock had previously closed at $6.19.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CMPX. D. Boral Capital reissued a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, December 3rd. Raymond James Financial reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Canaccord Genuity Group began coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Stock Up 3.6%

The stock has a market capitalization of $1.14 billion, a P/E ratio of -14.24 and a beta of 1.45. The stock’s 50 day moving average price is $5.37 and its 200-day moving average price is $4.21.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. Analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CMPX. Victory Capital Management Inc. increased its holdings in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Compass Therapeutics by 16.2% during the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Compass Therapeutics by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock valued at $619,000 after acquiring an additional 3,329 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Compass Therapeutics in the fourth quarter valued at approximately $32,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.